Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Specialized Biomedical Research Services

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract for Specialized Biomedical Research Services supports prime contractors on Defense Health Agency research awards. The scope of work involves performing specialized laboratory tests, assays, and analysis on breast cancer samples, as well as executing in vivo or in vitro experiments and proof-of-concept studies for translational research. These activities utilize advanced technology, including bioreactors, sequencing machines, and specialized imaging equipment, while maintaining strict compliance with IACUC and IRB standards. The selected provider is responsible for delivering raw data, analyzed results, and comprehensive technical reports. This opportunity falls under NAICS code 541715 and is associated with the Department of Defense. The response deadline for this requirement is November 18, 2026.

General Info

Subcontract for DHA breast cancer research services and lab analysis due November 18, 2026.

Agency

Department Of Defense → Defense Health Agency Contracting Activity - DhacaView Agency

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of HT942526BCRPBTA122.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

DoW Breast Cancer, Breakthrough Award Levels 1 and 2

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs specialized laboratory tests, assays, and analysis on breast cancer samples for prime contractors on Defense Health Agency research awards. Executes in vivo or in vitro experiments and proof-of-concept studies for translational research using bioreactors, sequencing machines, and specialized imaging equipment. Maintains compliance with IACUC and IRB standards. Delivers raw data, analyzed results, and technical reports.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
New
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Department of Defense, through the Defense Health Agency Contracting Activity, is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation number HT942526BCRPBTA122. This mechanism is designed to support high-potential research aimed at achieving breakthroughs in breast cancer, requiring all applications to address at least one overarching FY26 BCRP challenge or provide a strong justification for an exception. The program offers two funding levels with distinct research scopes, including a Population Science Studies option under Level 2 that may allow for increased funding and an extended period of performance. Eligible applicants may apply as a single Principal Investigator or through a partnering arrangement involving an Initiating PI and a Partnering PI. The application process follows a two-step sequence, with pre-applications due by November 4, 2026, and full applications due by November 18, 2026. For those utilizing the Partnering PI Option, both investigators must submit full applications to avoid administrative withdrawal. The program emphasizes a focus on research that can lead to clinical application and major impact, with all submissions governed by specific registration and review criteria managed by the grantor.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

in 2 months
View Details